Get started
Author

A Gilabert-Perramon

Observed names: A Gilabert Perramon, A. Gilabert, A. Gilabert Perramon, A. Gilabert-Perramon, Antoni Gilabert, Antoni Gilabert Perramon, Antoni Gilabert-Perramon, Antoni Gilabert-Perramon., Antoni Gilabert-Perramón, Antoni Gilabert-perramon, Gilabert Perramon, Antoni, Gilabert-Perramon, Antoni
ORCID: 0000-0003-3276-0170
Observed ORCID: 0000-0003-3276-0170
OpenAlex ID: A5039941946
Drug Evaluation and Decision Making in Catalonia: Development and Validation of a Methodological Framework Based on Multi-criteria Decision Analysis (mcda) for Orphan Drugs
2017 · Antoni Gilabert-Perramon, Josep Torrent-Farnell, et al. · International Journal of Technology Assessment in Health Care · 84
Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer
2016 · Ana Clopes, Montse Gasol, et al. · Journal of Medical Economics · 39
PDF
Multi-Criteria Decision Analysis (MCDA): Common Tools for Different Needs Supporting Healthcare Decision Making in Spain
2016 · A Gilabert-Perramon, C Lens, et al. · Value in Health · 16
Evaluation of electronic prescription implementation in polymedicated users of Catalonia, Spain: a population-based longitudinal study
2014 · Irene Lizano-Díez, Pilar Modamio, et al. · BMJ Open · 15
PDF
Implantación de medicamentos genéricos (EFG) en España y Cataluña: posibilidades de ahorro
2000 · M. Torralba Guirao, A. Gilabert Perramon, et al. · Atención Primaria · 15
PDF
The Effect of the Drug-Related Problems Prevention Bundle on Early Readmissions in Patients From the Emergency Department: A Randomized Clinical Trial
2022 · Ana Juanes, Jesús Ruíz, et al. · Annals of Pharmacotherapy · 14
The Impact of New Drug Introduction on Drug Expenditure in Primary Health Care in Catalunya, Spain
2004 · Corinne Zara, Miguel Torralba, et al. · Annals of Pharmacotherapy · 14
Receta electrónica en Cataluña (Rec@t): una herramienta de salud
2010 · Antoni Gilabert-Perramon, Pilar López-Calahorra, et al. · Medicina Clínica · 13
Profile, cost and pattern of prescriptions for polymedicated patients in Catalonia, Spain
2013 · Irene Lizano-Díez, Pilar Modamio, et al. · BMJ Open · 11
PDF
Multi-Criteria decision analysis in healthcare its usefulness and limitations for decision making
2018 · Néboa Zozaya González, Juan Oliva Moreno, et al. · Fundación Weber eBooks · 9
Introducing concepts of circular economy into the public procurement of medicines in Europe
2018 · Josep Maria Guiu Segura, Antoni Gilabert Perramon, et al. · European Journal of Hospital Pharmacy · 6
Guidance For Economic Evaluation and Budget Impact Analysis For Pharmaceuticals in Catalonia (Spain)
2014 · R. Mora-Ripoll, A. Gilabert-Perramon, et al. · Value in Health · 6
PDF
Estudio para la determinación de medidas de resultados en salud relevantes en el trastorno por consumo de opiáceos. Análisis de decisión multicriterio
2020 · Joan Colom, Nestor Szerman, et al. · Adicciones · 3
PDF
El Análisis de Decisión Multi-Criterio en el ámbito sanitario: utilidad y limitaciones en la toma de decisiones
2018 · Néboa Zozaya González, Juan Oliva Moreno, et al. · Fundación Weber eBooks · 3
La receta electrónica en Cataluña (Rec@t): ¿prescribimos o recetamos?
2009 · Antoni Gilabert, Rafel Cubí · Atención Primaria · 3
PDF
Los servicios farmacéuticos desde la perspectiva asistencial. Análisi de situación y líneas estratégicas
2000 · Josep Lluís Segú Tolsà, T. Casasín, et al. · Pharmaceutical care España · 3
Medicamentos biosimilares: medidas para fomentar su uso
2019 · Josep Maria Guiu Segura, Antoni Gilabert Perramon · Medicina Clínica · 2
Including management criteria for hazardous drugs in the drug procurement process
2018 · Josep M. Guiu Segura, Ferran Bossacoma Busquets, et al. · Research in Social and Administrative Pharmacy · 2
HT5 Development of a Multi-Criteria Decision Analysis (MCDA) Framework for Health Care Decision-Making in Catalonia (Spain): Pilot Study Focused in Orphan Drugs
2016 · A Gilabert-Perramon, J Torrent-Farnell, et al. · Value in Health · 2
PDF
Letter to the editor regarding the paper by A. Lozano-Blázquez et al. Differences in cancer drug assessment between Spain and the United Kingdom
2016 · Alba Prat, Antoni Gilabert, et al. · European Journal of Cancer · 2
Biosimilar drugs: Measures to promote their use
2020 · Josep Maria Guiu Segura, Antoni Gilabert Perramon · Medicina Clínica (English Edition) · 1
La experiencia de gestión de los medicamentos en Cataluña: objetivos de salud y económicos
2019 · A Gilabert-Perramon · Papeles de economía española/Papeles de economía española · 1
Can the Ethical Dilemmas for Health Care Decision Making on Drug Reimbursment Be Tackled Through Holistic Mcda: an Adaptation of the Evidem Framework in Real-world Setting - the Catalan Experience
2016 · X. Badia, H. Khoury, et al. · Value in Health · 1
Evaluation Of A Payment By Results Scheme In A Catalan Cancer Center: Gefinitib In Egfr Mutation-Positive Advanced Non-Small Cell Lung Cancer
2015 · S Simon, A Clopes, et al. · Value in Health · 1
Instrumentos Para la Incorporacion de la Evaluacion Economica, el Impacto Presupuestario y Los Esquemas de Pago por Resultados en el Servicio Catalán de Salud (España)
2015 · M Brosa, J Puig-Junoy, et al. · Value in Health · 1
Works count: 45
Citation count: 269
H-index: 9
I10-index: 9
Year
Topic
Type